Tags

Type your tag names separated by a space and hit enter

Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.
World J Gastroenterol 2013; 19(40):6911-8WJ

Abstract

AIM

To investigate the relationship between the gut-liver axis and nonalcoholic fatty liver disease (NAFLD), we performed a meta-analysis to evaluate the effects of probiotic therapy in NAFLD.

METHODS

We searched PubMed, Medline, Embase, Web of Science, the Cochrane Library and Chinese Biomedicine Database for all relevant randomized controlled trials on probiotics in patients with NAFLD/nonalcoholic steatohepatitis (NASH). A statistical analysis was performed using RevMan 5.0 software.

RESULTS

Four randomized trials involving 134 NAFLD/NASH patients were included. The results showed that probiotic therapy significantly decreased alanine aminotransferase (ALT), aspartate transaminase (AST), total-cholesterol (T-chol), high density lipoprotein (HDL), tumor necrosis factor (TNF)-α and homeostasis model assessment of insulin resistance (HOMA-IR) [ALT: weighted mean difference (WMD) -23.71, 95%CI: -33.46--13.95, P < 0.00001; AST: WMD -19.77, 95%CI: -32.55--7.00, P = 0.002; T-chol: WMD -0.28, 95%CI: -0.55--0.01, P = 0.04; HDL: WMD -0.09, 95%CI: -0.16-0.01, P = 0.03; TNF-α: WMD -0.32, 95%CI: -0.48--0.17, P < 0.0001; HOMA-IR: WMD -0.46, 95%CI: -0.73--0.19, P = 0.0008]. However, the use of probiotics was not associated with changes in body mass index (BMI), glucose (GLU) and low density lipoprotein (LDL) (BMI: WMD 0.05, 95%CI: -0.18-0.29, P = 0.64; GLU: WMD 0.05, 95%CI: -0.25-0.35, P = 0.76; LDL: WMD -0.38, 95%CI: -0.78-0.02, P = 0.06).

CONCLUSION

Probiotic therapies can reduce liver aminotransferases, total-cholesterol, TNF-α and improve insulin resistance in NAFLD patients. Modulation of the gut microbiota represents a new treatment for NAFLD.

Authors+Show Affiliations

Yan-Yan Ma, Lin Li, Chao-Hui Yu, Zhe Shen, Li-Hua Chen, You-Ming Li, Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24187469

Citation

Ma, Yan-Yan, et al. "Effects of Probiotics On Nonalcoholic Fatty Liver Disease: a Meta-analysis." World Journal of Gastroenterology, vol. 19, no. 40, 2013, pp. 6911-8.
Ma YY, Li L, Yu CH, et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2013;19(40):6911-8.
Ma, Y. Y., Li, L., Yu, C. H., Shen, Z., Chen, L. H., & Li, Y. M. (2013). Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World Journal of Gastroenterology, 19(40), pp. 6911-8. doi:10.3748/wjg.v19.i40.6911.
Ma YY, et al. Effects of Probiotics On Nonalcoholic Fatty Liver Disease: a Meta-analysis. World J Gastroenterol. 2013 Oct 28;19(40):6911-8. PubMed PMID: 24187469.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. AU - Ma,Yan-Yan, AU - Li,Lin, AU - Yu,Chao-Hui, AU - Shen,Zhe, AU - Chen,Li-Hua, AU - Li,You-Ming, PY - 2013/06/30/received PY - 2013/08/24/revised PY - 2013/09/03/accepted PY - 2013/11/5/entrez PY - 2013/11/5/pubmed PY - 2014/4/9/medline KW - Insulin resistance KW - Liver function KW - Meta-analysis KW - Nonalcoholic fatty liver disease KW - Nonalcoholic steatohepatitis KW - Probiotics SP - 6911 EP - 8 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 19 IS - 40 N2 - AIM: To investigate the relationship between the gut-liver axis and nonalcoholic fatty liver disease (NAFLD), we performed a meta-analysis to evaluate the effects of probiotic therapy in NAFLD. METHODS: We searched PubMed, Medline, Embase, Web of Science, the Cochrane Library and Chinese Biomedicine Database for all relevant randomized controlled trials on probiotics in patients with NAFLD/nonalcoholic steatohepatitis (NASH). A statistical analysis was performed using RevMan 5.0 software. RESULTS: Four randomized trials involving 134 NAFLD/NASH patients were included. The results showed that probiotic therapy significantly decreased alanine aminotransferase (ALT), aspartate transaminase (AST), total-cholesterol (T-chol), high density lipoprotein (HDL), tumor necrosis factor (TNF)-α and homeostasis model assessment of insulin resistance (HOMA-IR) [ALT: weighted mean difference (WMD) -23.71, 95%CI: -33.46--13.95, P < 0.00001; AST: WMD -19.77, 95%CI: -32.55--7.00, P = 0.002; T-chol: WMD -0.28, 95%CI: -0.55--0.01, P = 0.04; HDL: WMD -0.09, 95%CI: -0.16-0.01, P = 0.03; TNF-α: WMD -0.32, 95%CI: -0.48--0.17, P < 0.0001; HOMA-IR: WMD -0.46, 95%CI: -0.73--0.19, P = 0.0008]. However, the use of probiotics was not associated with changes in body mass index (BMI), glucose (GLU) and low density lipoprotein (LDL) (BMI: WMD 0.05, 95%CI: -0.18-0.29, P = 0.64; GLU: WMD 0.05, 95%CI: -0.25-0.35, P = 0.76; LDL: WMD -0.38, 95%CI: -0.78-0.02, P = 0.06). CONCLUSION: Probiotic therapies can reduce liver aminotransferases, total-cholesterol, TNF-α and improve insulin resistance in NAFLD patients. Modulation of the gut microbiota represents a new treatment for NAFLD. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/24187469/full_citation L2 - http://www.wjgnet.com/1007-9327/full/v19/i40/6911.htm DB - PRIME DP - Unbound Medicine ER -